CLAIMS

What is claimed is:

1. Use of an anti-CGRP antibody comprising the light chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224; SEQ ID NO: 226; and SEQ ID NO: 228, respectively and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204; SEQ ID NO: 206; and residues GDI, in the manufacture of a medicament for the treatment of cluster headache in a patient in need of immediate relief of symptoms,

wherein said anti-CGRP antibody is to be administered via intravenous infusion to the patient in a dosage of 400 mg of said anti-CGRP antibody,

wherein the symptom is head pain, and

wherein said symptom declines immediately after administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.

2. The use according to claim 1, wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222 and the variable heavy chain polypeptide of SEQ ID NO: 202.

3. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201 or SEQ ID NO: 566.

4. The use according to any one of the foregoing claims, wherein said intravenous administration is infused over a period of 30 min to 60 minutes.

5. The use of any one of the preceding claims, wherein said anti-CGRP antibody is to be administered intravenously in a dosage of about 400 mg of said anti-CGRP antibody every 10-14 weeks, preferably every 11-13 weeks, more preferably every 12 weeks.

6. The use of any one of the foregoing claims, wherein said anti-CGRP antibody is comprised in a formulation comprising or consisting of histidine (L-histidine), sorbitol, polysorbate 80, and water.

7. The use of claim 6, wherein said formulation comprises or consists of, per 1 mL volume, 100 mg anti-CGRP antibody, 3.1 mg L-Histidine, 40.5 mg Sorbitol, and 0.15 mg Polysorbate 80, or having amounts of each constituent within +/- 1% of said values, and having a pH of 5.8 or within +/- 1% of said value.

8. The use according to any one of claims 6 to 7, wherein said formulation comprises or consists of, per 1 mL volume, 100 mg anti-CGRP antibody, 3.1 mg L-Histidine, 40.5 mg Sorbitol, and 0.15 mg Polysorbate 80, or having amounts of each constituent within +/- 0.5% of said values, and/or having a pH of 5.8 or within +/- 0.5% of said value.

9. The use according to any one of claims 6-8, wherein said L- Histidine in said formulation comprises a mixture of L-Histidine and L-Histidine monohydrate.

10. The use according to any one of claims 6-9, wherein said formulation is comprised in a 100 mg/mL single-dose vial wherein each mL contains 100 mg anti-CGRP antibody, L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.

11. The use according to any one of claims 6-9, wherein said formulation is comprised in a 300 mg/mL single-dose vial wherein each mL contains 300 mg anti-CGRP antibody, L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.

12. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody is to be administered to a patient that exhibits a pain level of at most 2 or 3 on the VRS-4 immediately after administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.